The final, formatted version of the article will be published soon.
ORIGINAL RESEARCH article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 15 - 2024 |
doi: 10.3389/fimmu.2024.1500686
This article is part of the Research Topic Unveiling the Next Generation of Cancer Immunity & Immunotherapy View all 7 articles
Global Trends and Research Hotspots in Perioperative Management of Lung Cancer: A Bibliometric Analysis from 2004 to 2024
Provisionally accepted
Qinling Jiang
1*
Zhuheng Wei
2
Pingping Liu
3*
Zonghuai Li
2
Huiqin Jiang
1*
Yilin Cao
1*
Bo Zhang
2
Yuanyuan Yan
3*
Yulong He
1*- 1 Nanxishan Hospital of Guangxi Zhuang Autonomous Region, Gulin, Guangxi Zhuang Region, China
- 2 Guilin Medical University, Guilin, Guangxi Zhuang Region, China
- 3 The Third People's Hospital of Hainan Province, Sanya, China
Objective: This article aims to analyze the current status and research hotspots of literature related to perioperative management of patients with Lung Cancer and provide reference for future research directions. Methods: This study conducted a bibliometric analysis of research literature related to perioperative management of Lung Cancer published between 2004 and 2024, retrieved from the Web of Science database. R software and VOSviewer were used for analyzing keyword clusters and research themes, revealing trends and frontiers in this field. Results: A total of 4,942 studies on perioperative management of lung cancer were included. In recent years, research in this area has shown a global upward trend, with particular focus on surgical risk assessment, complication prevention, and postoperative management. Perioperative biomarkers before and after surgery have emerged as a central focus due to their impact on diagnosis and treatment. The application of novel therapies, such as targeted drugs and immunotherapy, in perioperative management is also becoming a significant research hotspot. Additionally, China has been a leading contributor to research output in this field, demonstrating strong performance in international collaborations.Perioperative management is a critical factor influencing the prognosis of Resectable lung cancer patients. Through a systematic analysis of the current status and research hotspots in perioperative management of lung cancer, this study provides valuable references for future clinical practice and research, particularly regarding the integration of novel therapies to optimize patient outcomes.
Keywords: lung cancer, Perioperative management, Immunotherapy, Targeted drugs, Bibliometric
Received: 23 Sep 2024; Accepted: 04 Nov 2024.
Copyright: © 2024 Jiang, Wei, Liu, Li, Jiang, Cao, Zhang, Yan and He. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Qinling Jiang, Nanxishan Hospital of Guangxi Zhuang Autonomous Region, Gulin, Guangxi Zhuang Region, China
Pingping Liu, The Third People's Hospital of Hainan Province, Sanya, China
Huiqin Jiang, Nanxishan Hospital of Guangxi Zhuang Autonomous Region, Gulin, Guangxi Zhuang Region, China
Yilin Cao, Nanxishan Hospital of Guangxi Zhuang Autonomous Region, Gulin, Guangxi Zhuang Region, China
Yuanyuan Yan, The Third People's Hospital of Hainan Province, Sanya, China
Yulong He, Nanxishan Hospital of Guangxi Zhuang Autonomous Region, Gulin, Guangxi Zhuang Region, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.